EUVIMEDDescoperă EUVIMED
Multizentrische StudieOpen access · CC BY-NC-ND 4.0

Patient and healthcare professional acceptability of pharmacogenetic screening for DPYD and UGT1A1 : A cross sectional survey

Sarah Glewis iD, Mei Krishnasamy, Senthil Lingaratnam, Sam Harris, Craig Underhill, Chloe Georgiou, Mark Warren, Robert Campbell, Maarten IJzerman, Mussab Fagery, Ian Campbell, Jennifer H Martin iD and 3 more

Clinical and Translational Science · 2023-12 · 16 (12) · 2700-2708

DOI: 10.1111/cts.13664 ↗

At a glance

Multizentrische Studie in Clinical and Translational Science, published online on 2023-10-31. Written by Sarah Glewis and 14 co-authors. Institution: Department of Pharmacy, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Major MEDLINE topics: Dihydropyrimidine Dehydrogenase Deficiency, Neoplasms, Pharmacogenomic Testing. Cited 9 times so far (Crossref); 16 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

RezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

This study explored the acceptability of a novel pharmacist‐led pharmacogenetics (PGx) screening program among patients with cancer and healthcare professionals (HCPs) taking part in a multicenter clinical trial of PGx testing (PACIFIC‐PGx ANZCTR:12621000251820). Medical oncologists, oncology pharmacists, and patients with cancer from across four sites (metropolitan/regional), took part in an observational, cross‐sectional survey. Participants were recruited from the multicenter trial. Two study‐specific surveys were developed to inform implementation strategies for scaled and sustainable translation into routine clinical care: one consisting of 21 questions targeting HCPs and one consisting of 17 questions targeting patients. Responses were collected from 24 HCPs and 288 patients. The 5‐to‐7‐day PGx results turnaround time was acceptable to HCP (100%) and patients (69%). Most HCPs (92%) indicated that it was appropriate for the PGx clinical pharmacist to provide results to patients. Patients reported equal preference for receiving PGx results from a doctor/pharmacist. Patients and HCPs highly rated the pharmacist‐led PGx service. HCPs were overall accepting of the program, with the majority (96%) willing to offer PGx testing to their patients beyond the trial. HCPs identified that lack of financial reimbursements (62%) and lack of infrastructure (38%) were the main reasons likely to prevent/slow the implementation of PGx screening program into routine clinical care. Survey data have shown overall acceptability from patients and HCPs participating in the PGx Program. Barriers to implementation of PGx testing in routine care have been identified, providing opportunity to develop targeted implementation strategies for scaled translation into routine practice.

Subjects

MeSH terms (MEDLINE)

Dihydropyrimidine Dehydrogenase DeficiencyNeoplasmsPharmacogenomic TestingHumansCross-Sectional StudiesHealth PersonnelPatient Acceptance of Health CarePharmacogeneticsUGT1A1 EnzymeDihydrouracil Dehydrogenase (NADP)

Substances

UGT1A1 EnzymeDPYD protein, humanDihydrouracil Dehydrogenase (NADP)

Authors and institutions

  • Department of Pharmacy, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.
  • Academic Nursing Unit, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • VCCC Alliance, Melbourne, Victoria, Australia.
  • Department of Medical Oncology, Bendigo Health, Bendigo, Victoria, Australia.
  • Border Medical Oncology Research Unit, Albury Wodonga Regional Cancer Centre, East Albury, New South Wales, Australia.

ORCID profiles: Sarah Glewis, Jennifer H Martin, Marliese Alexander

Cite

APA

Glewis, S., Krishnasamy, M., Lingaratnam, S., Harris, S., Underhill, C., Georgiou, C., Warren, M., Campbell, R., IJzerman, M., Fagery, M., Campbell, I., Martin, J. H., Tie, J., Alexander, M., & Michael, M. (2023). Patient and healthcare professional acceptability of pharmacogenetic screening for DPYD and UGT1A1 : A cross sectional survey. Clinical and Translational Science, 16(12), 2700-2708. https://doi.org/10.1111/cts.13664

Vancouver

Glewis S, Krishnasamy M, Lingaratnam S, Harris S, Underhill C, Georgiou C, et al. Patient and healthcare professional acceptability of pharmacogenetic screening for DPYD and UGT1A1 : A cross sectional survey. Clinical and Translational Science. 2023;16(12):2700-2708. doi:10.1111/cts.13664

BibTeX
@article{Glewis2023,
  author = {Glewis, Sarah and Krishnasamy, Mei and Lingaratnam, Senthil and Harris, Sam and Underhill, Craig and Georgiou, Chloe and Warren, Mark and Campbell, Robert and IJzerman, Maarten and Fagery, Mussab and Campbell, Ian and Martin, Jennifer H and Tie, Jeanne and Alexander, Marliese and Michael, Michael},
  title = {Patient and healthcare professional acceptability of pharmacogenetic screening for DPYD and UGT1A1 : A cross sectional survey},
  journal = {Clinical and Translational Science},
  year = {2023},
  volume = {16},
  number = {12},
  pages = {2700--2708},
  doi = {10.1111/cts.13664}
}
Start for free →